Season 1 Episode 447
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Ey's 2025 Biotech Beyond Borders report reveals that over one-third of biotech companies have less than a year of cash left, indicating financial challenges within the industry. The report emphasizes the need for a return to basics for biotech companies. Additionally, industry experts are discussing FDA Commissioner Makary's push to modernize the FDA and speed up regulatory processes. Scholar Rock has seen positive results with a weight loss combination therapy, and the FDA's new voucher program has been met with some optimism from biotech investors. Overall, the biotech industry is facing financial struggles, but there are opportunities for growth and innovation in the future.BioNTech and CureVac were once enemies, with BioNTech attacking CureVac's "failed" COVID vaccine program. However, they are now merging, with BioNTech buying CureVac in a $1.25 billion all-stock acquisition. The biopharma industry has seen a string of dramatic deals, with companies paying high premiums for acquisitions. This includes Sanofi paying a 300% premium for Vigil Neuroscience and Novartis acquiring Regulus for $800 million upfront. Overseas biosimilars companies can be sued in the US, potentially dissuading them from targeting the US market and benefiting domestic producers. Lilly's $1.3 billion acquisition of Verve in the gene editing space has been met with skepticism from analysts. Biotechs are seeking partnerships as the industry moves forward, with events like BIO2025 kicking off. The industry is facing challenges such as layoffs at companies like Lycia, while AstraZeneca makes a $5.3 billion AI bet with China's CSPC for chronic disease pills. Overall, the biopharma industry is experiencing a period of intense deal-making and strategic shifts.
Published on 5 months, 3 weeks ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate